DepoMed Dodges Patent Infringement Lawsuit
DepoMed Inc. (NASDAQ: DEPO) was up $0.47 (16.61%) today to $3.30 on news that no patent infringement lawsuit has been filed against the company over their experimental neuropathic pain drug, DM-1796.  As a result, the company expects to gain marketing approval of the drug in the first quarter of next year. DepoMed Inc. is a biopharm company most well known for its drugs GLUMETZA, used for the treatment of type 2 diabetes, and Proquin XR, used for the treatment of uncomplicated urinary tract infection.  DM-1796 will be used for the treatment of epileptic seizures. -Michael B. Sauter (Source: BioHealth Investor)

Is Depo Enough to Keep them Safe? Opportunities to Engage Adolescents for STI HIV Prevention
The objective of this study is to determine risk for STIs/HIV among long-acting contraceptive users and to identify potential opportunities for STI/HIV prevention among this population of urban adolescent girls. (Source: Journal of Pediatric and Adolescent Gynecology)div id=medwormpbiMedWorm Message:/i/b Please have a look at this new site driven by MedWorm: a href=http://www.thebreastcancerdaily.com/ target=_blankThe Breast Cancer Daily/a/p/div